Synthesis and Preclinical Evaluation of Novel <sup>99m</sup>Tc-Labeled FAPI-46 Derivatives with Significant Tumor Uptake and Improved Tumor-to-Nontarget Ratios-Reference-Cited by-同舟云学术

Synthesis and Preclinical Evaluation of Novel ^99mTc-Labeled FAPI-46 Derivatives with Significant Tumor Uptake and Improved Tumor-to-Nontarget Ratios

Published:2024-02-06 Issue: Volume: Page:
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Ruan Qing¹²,Ding Dajie¹,Diao Lina¹,Feng Junhong¹,Yin Guangxing¹,Jiang Yuhao¹,Wang Qianna¹,Han Peiwen¹,Jiang Jianyong²,Zhang Junbo¹^ORCID

Affiliation:

1. Key Laboratory of Radiopharmaceuticals of the Ministry of Education, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China

2. Key Laboratory of Beam Technology of the Ministry of Education, College of Nuclear Science and Technology, Beijing Normal University, Beijing 100875, P. R. China

Funder

China Postdoctoral Science Foundation

Beijing Municipal Natural Science Foundation

Beijing Nova Program

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00031

Reference35 articles.

1. Cancer-associated fibroblasts and its derived exosomes: a new perspective for reshaping the tumor microenvironment

2. Research progress on the role of fibroblast activation protein in diagnosis and treatment of cancer

3. Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy

4. Role of stromal myofibroblasts in invasive breast cancer: stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome